Salix Pharmaceuticals and Pharming have announced US Food and Drug Administration (FDA) approval of Ruconest for treatment of acute angioedema attacks in adult and adolescent patients with hereditary angioedema (HAE).

The FDA has approved the company’s biologics licence application for Ruconest, a C1 esterase inhibitor [recombinant], based on a Phase III trial (RCT) that included an open-label extension (OLE) phase and is supported by results of two additional RCTs and two additional OLE studies.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The pivotal RCT and OLE studies included 44 patients who experienced 170 HAE attacks. The primary efficacy endpoint was the time to beginning of symptom relief, assessed using patient-reported responses to two questions about the change in overall severity of their HAE attack symptoms after the start of treatment.

“Ruconest is the first recombinant replacement therapy for C1Inhibitor deficiency.”

Headache, nausea, and diarrhoea were the most common adverse reactions, while anaphylaxis was the serious adverse reaction in clinical studies of Ruconest.

Pharming CEO Sijmen de Vries said: “The approval of Ruconest in the US is a very significant milestone for Pharming.

“For many years we have strived to make Ruconest, the first recombinant replacement therapy for C1Inhibitor deficiency, available to the HAE patient community in the US, because we were aware of the great value and benefit this product adds to patients’ lives.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“Today we are proud to have achieved this goal in the US.”

Ruconest is manufactured by Pharming in the Netherlands and Salix Pharmaceuticals has licensed exclusive rights from Pharming to commercialise the drug in North America.

Salix Pharmaceuticals currently plans on making Ruconest accessible to patients later this year.